Here are 1-3 brief analogies for Organigram Global (OGI):

• The Molson Coors of cannabis.
• Anheuser-Busch InBev for marijuana.
• A Constellation Brands for weed.

• Medical Cannabis Products: Offers cannabis flowers, oils, and vaporizers to civilian patients and veterans.
• Adult-Use Recreational Cannabis Products: Sells various recreational cannabis products under brands like SHRED, Big Bag O' Buds, and Monjour.
• Cannabis Edibles: Provides a range of edible products infused with cannabis.
• Cannabis Concentrates: Offers concentrated forms of cannabis and cannabis-derived products.
• Wholesale Cannabis Supply: Engages in wholesale shipping of cannabis plant cuttings, dried flowers, and derivative products to retailers and wholesalers.

Organigram Global (OGI) sells primarily to other companies, specifically to provincial cannabis boards and licensed wholesalers/distributors across Canada for adult-use recreational cannabis. While Organigram produces and brands products for individual consumers (e.g., Edison Cannabis Co., SHRED, Monjour), its direct customers for the recreational market are these provincial entities and large retailers.

The major customers are the provincial cannabis distributors and wholesalers in various Canadian provinces. These entities are typically government-owned or regulated bodies responsible for the distribution of cannabis within their respective jurisdictions. They do not have public company stock symbols.

Examples of such major customers include, but are not limited to:

• Ontario Cannabis Store (OCS)
• Société québécoise du cannabis (SQDC)
• Alberta Gaming, Liquor & Cannabis (AGLC)
• BC Liquor Distribution Branch (BCLDB)
• Manitoba Liquor & Lotteries (MBLL)
• Cannabis New Brunswick (Cannabis NB)
• Nova Scotia Liquor Corporation (NSLC)
• Prince Edward Island Cannabis Management Corporation (PEICMC)
• Newfoundland and Labrador Liquor Corporation (NLC)

Organigram also sells directly to medical cannabis patients (civilian and veterans), representing a smaller portion of its overall customer base compared to the wholesale recreational market.

James Yamanaka, Chief Executive Officer

James Yamanaka was appointed Chief Executive Officer of Organigram Global Inc. effective January 15, 2026. He has over 20 years of experience at British American Tobacco (BAT), where he most recently served as Global Head of Strategy and was instrumental in developing the group's strategy. His background includes extensive experience in strategy and general management across Europe and Asia. Prior to his global strategy role, he was Area Director for North Asia, where he achieved record market share in Japan. He also transformed BAT's Northern Europe Area by acquiring a nicotine pouch business, positioning it for sustainable growth. Mr. Yamanaka holds a BA in Political Science and Economics from UC San Diego, an M.S. in Foreign Service from Georgetown University, and an MBA from London Business School.

Greg Guyatt, Chief Financial Officer

Greg Guyatt was appointed Chief Financial Officer of Organigram Holdings Inc. effective January 8, 2024. He is a financial executive with over 25 years of experience in international public and private equity-backed companies. Before joining Organigram, Mr. Guyatt served as the Chief Financial Officer of Phoena before becoming its CEO in 2020. His previous roles include Chief Financial Officer of Greenspace Brands and senior finance positions at Kingsett Capital and Sears Canada.

Helen Martin, Chief Legal Officer, Corporate Secretary

Helen Martin serves as the Chief Legal Officer and Corporate Secretary for Organigram Holdings Inc.

Timothy (Tim) Emberg, Chief Commercial Officer

Timothy Emberg holds the position of Chief Commercial Officer at Organigram Holdings Inc.

Megan Amber McCrae, Senior Vice President - Global Brands and Corporate Affairs

Megan Amber McCrae is the Senior Vice President of Global Brands and Corporate Affairs at Organigram Holdings Inc.

The key risks for Organigram Global (OGI) include:

1. Regulatory and Legal Environment: As a company operating in the highly regulated cannabis industry in Canada, Organigram is susceptible to significant changes in federal and provincial laws and regulations. These changes could pertain to cultivation, processing, distribution, marketing, product types, or taxation, all of which could materially impact Organigram's operations, market access, and profitability. The ongoing evolution of cannabis legislation introduces uncertainty and the need for continuous adaptation.

2. Intense Competition and Market Saturation: The Canadian cannabis market, encompassing both medical and adult-use recreational segments, is characterized by a large number of licensed producers and intense competition. This competitive landscape can lead to price compression, decreased profit margins, and challenges for Organigram in maintaining or expanding its market share across its brands such as Edison Cannabis Co., SHRED, and Monjour. The persistent presence of the illicit cannabis market also provides a source of competition due to often lower prices and absence of regulatory compliance costs.

3. Shifting Consumer Preferences and Product Innovation: The cannabis market is dynamic, with consumer preferences for product formats (e.g., dried flower, oils, edibles, vapes) and specific characteristics (e.g., cannabinoid profiles, strains) continually evolving. Organigram's success relies on its ability to effectively anticipate these shifts and innovate its product offerings to meet changing consumer demand. A failure to adapt quickly to new trends or to introduce compelling new products could result in a decline in sales and market relevance.

The emergence of synthetic and biosynthetic cannabinoid production poses a clear threat. These technologies, utilizing methods like yeast fermentation or chemical synthesis, could enable the creation of cannabinoids (like THC and CBD) with greater purity, consistency, and potentially at a significantly lower cost compared to traditional plant-based cultivation. If these alternative production methods become commercially viable at scale, they could fundamentally disrupt the market for cultivated cannabis, challenging the cost structure and agricultural-based business model of companies like Organigram Global.

The addressable markets for Organigram Global's main products and services in Canada are as follows:

• Overall Legal Cannabis Market (Canada): The total legal cannabis market in Canada was valued at approximately C$5.8 billion in 2024, with recreational sales accounting for about C$5.4 billion. More specifically, adult-use recreational cannabis sales reached C$5.5 billion in the fiscal year ending March 31, 2025, and C$5.62 billion for the full calendar year 2025.
• Medical Cannabis Products (Canada): The medical cannabis market in Canada generated revenue of USD 1,665.6 million in 2023 and is projected to reach USD 4,569.5 million by 2030.
• Adult-Use Recreational Cannabis Products (Canada): Adult-use recreational cannabis sales in Canada reached C$5.5 billion in the fiscal year ending March 31, 2025.
• Cannabis Edibles (Canada): Sales of cannabis edibles in Canada were C$219 million in the 2024/2025 fiscal year.
• Cannabis Concentrates (Canada): "Inhaled Cannabis Extracts," which include vape pens, hash, wax, and rosin, grew to C$1.7 billion in the 2024/2025 fiscal year. "Ingested cannabis extracts," covering oils, capsules, and sprays, amounted to C$170.4 million in the same fiscal year. The broader Canada cannabis extract market generated USD 350.2 million in 2023 and is expected to reach USD 1,136.3 million by 2030.
• Vaporizers (Canada): Cannabis vapes were the third-largest product category, representing 32% of total sales in Q1 2025. This aligns with the C$1.7 billion for "Inhaled Cannabis Extracts" in the 2024/2025 fiscal year. The Canada cannabis vape market generated USD 314.9 million in 2024 and is expected to reach USD 695.3 million by 2030.
• Wholesale Shipping of Cannabis (Canada): Wholesale trade and sales for cannabis merchant wholesalers in Canada peaked at approximately $288 million per month in 2024 and 2025, indicating an annual market size of around C$3.456 billion for these activities. The "Cannabis Growing" industry in Canada, which includes the wholesale of plant materials, is estimated at $13.0 billion in 2026.

1. International Market Expansion: Organigram anticipates significant revenue growth from its expanding international footprint. The company is actively focusing on increasing sales in key markets such as Germany, the U.K., Australia, and Israel, and has begun early activities in the U.S. hemp-derived THC market. Efforts to secure EU GMP certification for its Moncton facility are expected to further boost export volumes to these international destinations.
2. Canadian Market Leadership and Product Innovation: Organigram aims to maintain and grow its leading market share in the Canadian recreational cannabis segment. The company plans to drive revenue by launching new products and enhancing its existing portfolio, particularly in high-growth categories like vapes, milled flower, concentrates, and pre-rolls, where it holds strong market positions. Examples include new vapes, coated infused pre-rolls, and various cannabis beverages.
3. Strategic Acquisitions and Integration: Recent acquisitions, such as Motif Labs and Collective Project, are expected to contribute to revenue growth by expanding Organigram's operational capabilities and market reach. These integrations enhance the company's extraction capabilities and provide entry into new product segments, including cannabinoid beverages in both Canadian and U.S. markets.
4. Operational Efficiencies and Increased Production Yields: Investments in advanced cultivation techniques and technologies, such as converting grow facilities to LEDs, adopting seed-based growing, and identifying genetic markers for powdery mildew resistance, are leading to increased yields and reduced production costs. These efficiencies are expected to allow for higher output and potentially more competitive pricing, thereby supporting overall revenue growth.

Share Repurchases

• Organigram has not reported significant share repurchases over the last 3-5 years, with financial statements indicating no repurchase of common stock.

Share Issuance

• The number of Organigram's shares outstanding increased by 29.06% in one year (prior to March 2026).
• British American Tobacco (BAT) is set to subscribe for approximately 14 million common shares and exercise top-up rights for nearly 10 million shares, totaling C$65.2 million, as part of a private placement in February 2026, largely tied to an acquisition.
• The acquisition of Collective Project includes potential earnout payments, with the first earnout, if applicable, expected to be paid 50% in cash and 50% in Organigram share consideration.

Inbound Investments

• British American Tobacco (BAT) made a strategic investment of C$221 million in 2021.
• BAT further invested C$125 million in 2024, establishing the "Jupiter" strategic investment pool, with C$83.1 million allocated for emerging cannabis opportunities.
• In February 2026, BAT provided a C$65.2 million private placement investment to help fund Organigram's proposed acquisition of Sanity Group.

Outbound Investments

• Organigram acquired Motif Labs Ltd. in Q1 Fiscal 2025 (December 2024), a move projected to generate C$15 million in annualized cost synergies and add C$87 million in sales.
• The company acquired Collective Project Limited in March 2025 for an upfront consideration of approximately C$6.2 million, with potential earnout payments of up to C$24 million, marking its entry into the U.S. hemp-derived THC beverage market and expanding its Canadian cannabis beverage offerings.
• Organigram made a C$21 million investment in Sanity Group, a German cannabis company, to establish a presence in the European market, with a proposed acquisition of Sanity Group announced in February 2026.

Capital Expenditures

• Capital expenditures were approximately C$12.76 million in the last 12 months prior to March 2026.
• The company utilized C$22 million for capital expenditures year-to-date prior to Q3 Fiscal 2023.
• Organigram is reevaluating C$8 million in previously disclosed capital expenditure investments related to grow room expansion due to recent capacity enhancements.